share_log

Vistagen Therapeutics Analyst Ratings

Benzinga ·  Nov 15, 2023 01:46
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/14/2023 269.23% Stifel → $12 Initiates Coverage On → Buy
09/05/2023 823.08% Maxim Group $30 → $30 Maintains Buy
08/07/2023 823.08% Maxim Group → $30 Upgrades Hold → Buy
07/26/2022 Maxim Group Downgrades Buy → Hold
07/22/2022 William Blair Downgrades Outperform → Market Perform
05/20/2021 176.92% Baird → $9 Initiates Coverage On → Outperform
02/18/2021 84.62% Jefferies → $6 Initiates Coverage On → Buy
01/04/2021 William Blair Upgrades Market Perform → Outperform
10/08/2020 84.62% Aegis Capital → $6 Initiates Coverage On → Buy
08/28/2019 William Blair Initiates Coverage On → Outperform
07/22/2019 -78.46% Chardan Capital $22 → $0.7 Downgrades Buy → Neutral

What is the target price for Vistagen Therapeutics (VTGN)?

The latest price target for Vistagen Therapeutics (NASDAQ: VTGN) was reported by Stifel on November 14, 2023. The analyst firm set a price target for $12.00 expecting VTGN to rise to within 12 months (a possible 269.23% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Vistagen Therapeutics (VTGN)?

The latest analyst rating for Vistagen Therapeutics (NASDAQ: VTGN) was provided by Stifel, and Vistagen Therapeutics initiated their buy rating.

When is the next analyst rating going to be posted or updated for Vistagen Therapeutics (VTGN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vistagen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vistagen Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.

Is the Analyst Rating Vistagen Therapeutics (VTGN) correct?

While ratings are subjective and will change, the latest Vistagen Therapeutics (VTGN) rating was a initiated with a price target of $0.00 to $12.00. The current price Vistagen Therapeutics (VTGN) is trading at is $3.25, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment